DEVA ABOUT US
Active since in 1958, DEVA Holding is one of the deep-rooted medicine manufacturers of Turkey.
With its main scope of business covering manufacturing and marketing of medicines for human use and raw materials, DEVA Holding also produces veterinary drugs, cologne and medical vials.
Majority shares of DEVA Holding were acquired in 2006 by the funds managed by GEM Global Equities Management S.A., an international fund management company, and EastPharma Ltd. was established to take on the management.
Aiming to offer innovative and different products with a high quality experience so that everyone can reach a healthy life on a global scale, to create giant drug brands in fields it competes and become the first preference DEVA Holding ranks at the fourth place and at the sixth place within its industry on box and turnover basis, respectively, according to IMS Health free market data.
DEVA Holding has been creating difference by releasing new products into market every single year.
DEVA Holding places puts emphasize on research and development activities so as to facilitate access by the patients to the medicines they could need. On this respect, DEVA Holdings’ facilities have received GMP (Good Manufacturing) compliance certification in 2012.
With its strong staff composed of more than 130 trained and specialized personnel, and its full-equipped laboratories fitted with the current technology and production sites, DEVA Holding has been developing innovative, novel forms and products with high added value. On the other hand, it has been striving to conduct the R&D activities in accordance with all ethical and legal arrangements so as to satisfy expectations of the respective authorities, to increase accessibility by proving with shelf life elongation efforts that safety, efficacy and quality of the product is not changed, to develop and adapt to production such methods aimed at increasing efficiency for sustainable growth.
DEVA Holding has become a domestic company which realizes the most comprehensive production in Turkey thanks to production facilities established. Carrying on its production in its production facilities located in Çerkezköy, Kartepe and Topkapı, DEVA Holding has an annual production capacity of 500 million boxes of medicine.
Taking the motto "human health is our indispensable priority no matter where they are" as the starting point, DEVA Holding also gives support to social responsibility projects.
We exist to offer innovative and diversified rang of products with a high quality experience enabling healthy life opportunity to be available to everyone on a global scale.
To become the first choice by creating robust pharmaceutical brands in the areas we compete in.
Transparency, result orientation, accountability.
Deva Holding observes its main principles in all its business processes and makes sure they are reflected in all its functions.
Integrity, quality, reliability, customer orientations, adherence to ethical values, independence, employee satisfaction, creativity, entrepreneurship, team work, environmentalism.
DEVA QUALITY CULTURE
QUALITY – CARE & INNOVATION
Deva quality reflects two fundamental principles of CARE and INNOVATION.
We care for our patients, customers, partners, employees and environment in which we manufacture our products. In taking care we provide a secure and ethical supply of products to underpin the DEVA brand and reputation.
We innovate our products, processes and management practices to enable our company to continously improve our service, our market share and to hold a competitive advantage. Through our innovative approaches we are able to maximiseshare holder investments.
QUALITY – CULTURE
Deva quality culture is founded upon the concept of “Right first time”. Each and every employee at Deva adopts it as a principle to ensure patient safety and excellence in operations.
Deva quality culture starts with product research and development and covers all processes from production through to our distribution networks.
QUALITY - SYSTEM
Deva quality management system ensures our care and innovative principles link directly to our quality culture. Our quality management system provides a framework of operational procedures that bring consistency and best practice to all of our manufacturing sites and also satisfies legal requirements and international levels of Good Manufacturing Practice (GMP). Throughout the quality management system risk managment techniques and pragmatic application exists.
QUALITY – UNDERSTANDING
Deva is driven by people with passion and understanding. In all aspects of our products deva employees strive for improvement and to seek out competitive advantage in both Turkey and International markets. Our people are dedicated and determined to match the challenges facing the pharmaceutical markets.
QUALITY – OUTLOOK 2011
Deva has successfully built a world class quality team and developed its system throughout 2010 to meet international quality and compliance standards. In 2011 DEVA has successfully met the audit requirements of local ministry of health regulators and international customers that rely on DEVA as a strategic manufacturing partner.
Our quality principles of care and innovation continue into 2011 with the launch of new innovative products completely developed by DEVA. Successful international inspection for 2011 will also be the focus of the company to open new markets and maximise our care to patients and shareholders.
Philipp Daniel Haas
President of the Board of Directors and CEO
Philipp Haas, Chairman of Board of Directors and CEO of DEVA Holding, took his MBA with a major in banking from St.Gallen Economy, Law and Business Administration University. He is fluent in German, English, French, Spanish, Portuguese, Italian and Turkish. Philipp D. Haas who has been working as investment advisor and manager since 1992 has a broad experience in the Eastern European countries and Turkey in particular. Having taken part in several restructuring projects in Ukraine and Turkey, Philipp D. Haas acted as member of several board of directors as representative of foreign corporate investors during the 90s, and Rogan Brewery of Ukraine and Net Holding of Turkey may be mentioned among others. Philipp D. Haas who has had a vast experience in pharmaceutical industry has provided funds with pharmaceutical industry advisory and helped them direct their investments into Eastern Europe. These included Slovakopharma which changed its name to Zentiva subsequently. Currently serving as Chairman of Board of Directors of EastPharma Ltd and DEVA Holding, Haas is also Chairman of Board of Directors at VetaşVeterinerveTarımİlaçları A.Ş., Saba İlaçSanayiveTicaret A.Ş., New Life YaşamSigorta A.Ş., EastPharmaİlaçÜretimPazarlama San. ve Tic. A.Ş. and a member of Board of Directors at EastPharmaSarl, LypanosysPteUmited. He has also been holding senior positions in other companies within the Group. Philipp D. Haas is Vice Chairman of the Board of Directors at Pharmaceutical Manufacturers Association of Turkey (TISD).
Vice-Chairman of Board of Directors and CFO
MesutÇetin, Vice Chairman of Board of Directors and CFO of DEVA Holding, worked at GEM Global Equities Management S.A. as executive in charge of operations between 2005 and 2006, and worked at the same group at different positions since 1999 such as analyst and project director. Mesut Çetin, EastPharma Ltd, Vetaş Veteriner Ve Tanm ilaçları A.Ş. ve Saba ilaç Sanayi ve Ticaret .AŞ.'de Yönetim Kurulu Üyesidir. He has also been holding senior positions in other companies within the Group. MesutÇetin graduated from Mathematics department of Boğaziçi University.
Beat Martin Schlagenhauf
Member of the Board of Directors
An independent member of Board directors of DEVA Holding, Beat Schlagenhauf has been acting as investment advisor and portfolio manager via Zurich-Switzerland based Schlagenhauf& Partner Portfolio Management firm owned by him. Before starting his own business in 1987, he worked at Rothschild Bank based in Zurich as portfolio manager and vice chairman for 9 years. Beat Schlagenhauf has been a member of Board of Directors of DEVA Holding since May 2011.
Member of the Board of Directors
CüneytDemirgüreş, and Independent Member of the Board of Directors of DEVA Holding, graduated from METU, Department of Electrical and Electronics Engineering followed by MBA in Boğaziçi University, and took Doctorate of Finance in University of Alabama between the years 1990 and 1993. Having assumed senior executive positions in financial institutions including Eczacıbaşı Securities, Demir Investment and Demirbank, Swiss Portfolio Management and Unicredit Securities, Demirgüreş is a member of Board of Directors at Baytur Motorlu Vas.Ticaret A.Ş. and Baylas Otomotiv A.Ş, and an academician at Koç University.
BOĞAZİÇİ (Lemon Cologne)
Boğaziçi Cologne, one of the most sold brands of Turkey in terms of sales figures, has been manufactured At Kartepe Plant. Production capacity of lemon cologne is 3,5 million liters, The brand Boğaziçi is still perceived one of the most prestigious brands in cologne industry. Since 1970, DEVA has been producing cologne under brand name Boğaziçi. Today, colognes in floral forms such as 80° Lemon, Lavender, After Shave are manufactured which attract various consumer groups, 80° Boğaziçi Lemon Cologne continues to be manufactured with the same odor form ever since 1970.
At this production plant, production capacity ratio was 53% in 2010.
VETAS VETERINARY AND AGRICULTURE MEDICALS A.Ş.
Established under the roof of DEVA Holding to deal with production and manufacturing of veterinary and agricultural products, Vetaş, as one of the pioneers in Turkish animal health drugs industry, takes part among the biggest 3 companies of the industry. Vetaş has largest product range with its innovative product scale, which produces high quality solutions in prevention, diagnosis and treatment of the diseases.
The animal farming industry that is very sensitive to seasonal changes was negatively affected by the increase in feed prices and unfavorable climate conditions in 2012. These conditions caused troubles in repayments of animal farming loans by the breeders resulting in sending of valuable breed animals to slaughterhouse and drops in meat and milk prices.
These troubles suffered in the animal farming industry caused the animal health drugs industry suffer a hard year. Considering all developments in the industry at the right time with the right strategies, Vetaş has achieved to maintain its throng position despite the troubles. Vetaş continued in 2012 as it has always done to meet the requirements in every aspect with the advanced technological infrastructure it owns for ensuring healthy, safe and efficient animal food production, by concentrating on new product efforts, it has focused on the projects of expanding its product range in line with the field dynamics.
It carried on organizing technical support and scientific vocational training seminars with the topics “General Approach to Herd Health and Metabolism Diseases” and “Protection and Treatment Protocols in Metabolism Diseases” for vets throughout Turkey. Vetaş became sponsor in the 13th Veterinary Surgery Congress, and was represented as participant in the Herd Health and Management Symposium, and 1st National Milk Summit that was held for the first time in our country.
Within the activities of new product developments and portfolio enrichment, Vetaş obtained 4 new product marketing authorizations and filed applications for marketing authorizations for 4 new products in 2012.
DEVA HOLDING .NZ.
It was established in New Zealand in order to sell and market drugs pertaining to Deva Holding and Vetaş Veteriner ve Tarım İlaçları A.Ş, its subsidiary, in Australia and New Zealand.
Level 1, 92 Spey Street, Invergargill 9840, New Zealand
Phone: +64 (3) 218 9911
Facsimile: +64 (3) 218 9933
Email address: firstname.lastname@example.org@deva.co.nz